Latigo Biotherapeutics (NASDAQ:LTGO) Director Purchases $2,520,000.00 in Stock

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) Director James Tananbaum acquired 140,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the transaction, the director owned 2,008,024 shares of the company’s stock, valued at $36,144,432. The trade was a 7.49% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Latigo Biotherapeutics Stock Performance

Latigo Biotherapeutics stock opened at $19.38 on Thursday. Latigo Biotherapeutics, Inc. has a 1-year low of $17.22 and a 1-year high of $22.47.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.